Work

Forced degradation of recombinant monoclonal antibodies: A practical guide

Year: 2017
Type: review
Abstract: Forced degradation studies have become integral to the development of recombinant monoclonal antibody therapeutics by serving a variety of objectives from early stage manufacturability evaluation to supporting comparability assessments both pre- and post- marketing approval. This review summarizes the regulatory guidance scattered throughout different documents to highlight the expectations from various agencies such as the Food and Drug Administration and European Medicines Agency. The various purposes for forced degradation studies, commonly used conditions and the major degradation pathways under each condition are also discussed.
Source: mAbs
Language: English
Open Access status: gold
Estimated APC paid: $3,575
Funder: Celgene
OpenAlex ID: W2751949649
FWCI: 1.562
Cites: 98
Cited by: 290
Related to: 10